Sign in Register

Drug class

Glycoprotein IIB/IIIA Receptor Inhibitor

A glycoprotein IIb/IIIa receptor inhibitor is a class of intravenous antiplatelet medication designed to prevent arterial thrombus formation. Read more about Glycoprotein IIB/IIIA Receptor Inhibitor

19 drugs in this class 14 manufacturers

Advertisement

Related classes & indications

Calcium Channel BlockersCardiovascular & renal · 344 prescription drugs Angiotensin II Receptor Antagonists (ARBs)Cardiovascular & renal · 281 prescription drugs

Drugs in Glycoprotein IIB/IIIA Receptor Inhibitor

Showing 10–18 of 19 drugs

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
ATHENEX PHARMAC

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
MEITHEAL PHARMA

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
AVENACY, INC

EPTIFIBATIDE

GLYCOPROTEIN IIB/IIIA RECEPTOR INHIBITOR · ACUTE CORONARY SYNDROME ·+1
SLATE/PREMIERPR
Filter & compare in the drug finder → Opens the drug finder with Glycoprotein IIB/IIIA Receptor Inhibitor preselected. Add indication or manufacturer filters there.

About Glycoprotein IIB/IIIA Receptor Inhibitor.

A glycoprotein IIb/IIIa receptor inhibitor is a class of intravenous antiplatelet medication designed to prevent arterial thrombus formation.

These agents work by selectively binding to the platelet membrane glycoprotein IIb/IIIa integrin complex, blocking fibrinogen and von Willebrand factor from cross-linking adjacent platelets during the final common pathway of platelet aggregation.

Clinically, they are primarily utilized in acute cardiovascular care, specifically for managing acute coronary syndromes such as unstable angina and non-ST elevation myocardial infarction, and as adjunctive therapy to reduce ischemic complications during percutaneous coronary intervention.